Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
11 April 2025 | Story Martinette Brits | Photo Supplied
Italian Design Day Competition Winners
National student competition winners, UFS's Gustav Pretorius and Jeanré Erasmus, pictured with Matteo Cibic and Michele Gialdroni, Director of the Italian Cultural Institute.

Two talented Architecture students from the University of the Free State (UFS), Jeanré Erasmus and Gustav Pretorius, have achieved national acclaim by winning the prestigious Italian Design Day 2025 Competition held in Pretoria. Their innovative exhibition space, inspired by The Dancer -  a dynamic ceramic sculpture by renowned South African artist Andile Dyalvane – captivated the judging panel and emerged victorious from among 45 entries submitted by 140 students from across South Africa.

 

Passion meets purpose 

For Erasmus, now in his third year of Architecture and working part-time at Soleil Architects, the path to this milestone began at an early age. “Ever since I was little, I’ve been obsessed with building things,” he recalls. His fascination with design and problem-solving naturally evolved into a passion for architecture, and he credits the UFS for providing a nurturing environment where both his technical skills and creative thinking could flourish. 

He credits his lecturers and peers for constantly challenging his ideas and pushing him towards excellence. He highlights the impact of former lecturer Martie Bitzer in shaping his journey. “We have an amazing, talented, and kind lecturer in Martie Bitzer, who has a big heart for architecture and her students,” he says. 

Pretorius, a fourth-year student, shares a similar drive. His design philosophy is deeply rooted in human experience and storytelling – an approach that played a key role in their winning design. “For me, architecture is not only about the physical form –  it is about how people interact with and move through space,” he explains. He believes their studies at UFS prepared them well to take on real-world challenges, equipping them with both conceptual depth and technical precision. 

 

Designing the story 

The Italian Design Day 2025 Competition, held on 24 February 2025 in Pretoria, tasked students with designing an exhibition space that captured the whimsical and narrative-rich aesthetic of renowned Italian designer Matteo Cibic. Instead of simply showcasing objects, the brief called for storytelling through design. 

Erasmus and Pretorius rose to the challenge by creating a space that echoed the movement and transformation embodied in Dyalvane’s The Dancer. “We didn’t want to use the static display cases,” explained Erasmus. “We designed the space that guided visitors through an interactive journey, rooted in the idea of shaping and refining - mirroring the movement and storytelling embedded in Dyalvane’s clay sculpture.”

Their concept impressed a panel of esteemed judges that included architects, Fanele Zondi and Braam de Villiers, and Stefania Iuliano, Commercial Attaché at the Italian Embassy in Pretoria. The panel’s combined expertise ensured a thorough evaluation of creativity, innovation, and spatial storytelling.

 

Overcoming creative challenges 

Developing a design that balanced imaginative expression with practical execution was no easy task.  “Picture two architecture students staring at a blank page late at night, questioning their life choices,” Erasmus jokes. One of the greatest challenges was translating a deeply emotional concept into a physical space - but through teamwork and continuous refinement, they achieved a balance between form and function.

“Like any great duo – Batman and Robin, peanut butter and jelly, architecture and last-minute deadlines – we balanced each other out,” Erasmus adds. Pretorius agrees, noting that their shared technical mindset kept the design process grounded in feasibility while still allowing room for creativity. Their ability to combine conceptual innovation with structural logic ultimately set their entry apart.

 

A milestone moment

When Erasmus received the call announcing their win, the moment was surreal. “It was a mix of shock and excitement, with a little bit of ‘Wait, is this a prank?’” he says. Although initially sworn to secrecy, the pair struggled to contain their excitement. “We didn’t exactly stick to that rule,” Erasmus admits with a laugh. 

Beyond the accolade, this experience has been transformative. “This experience has been like a masterclass in storytelling through space,” says Pretorius. “It reminded us that architecture is not just about buildings – it is about making people feel something.”

Looking ahead, both students are eager to continue exploring the narrative potential of architecture. Erasmus is particularly interested in how design intersects with various forms of artistic expression, while Pretorius plans to focus on sustainable and experiential design. They agree that the competition has reinforced their belief in architecture as a powerful tool for storytelling and human connection.

 

The winning exhibition space:

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept